Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126249252 | 12624925 | 2 | F | 20160815 | 20160805 | 20160819 | PER | US-PFIZER INC-2016367001 | PFIZER | 48.00 | YR | M | Y | 0.00000 | 20160819 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126249252 | 12624925 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 100 MG, 3X/DAY | 20235 | 100 | MG | CAPSULE, HARD | TID | ||||||
| 126249252 | 12624925 | 2 | SS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, 3X/DAY | 20235 | 300 | MG | CAPSULE, HARD | TID | ||||||
| 126249252 | 12624925 | 3 | SS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 400 MG, 3X/DAY OR MAYBE MORE | 20235 | 400 | MG | CAPSULE, HARD | TID | ||||||
| 126249252 | 12624925 | 4 | SS | GABAPENTIN. | GABAPENTIN | 1 | UNK, 1X/DAY(TAKEN UP TO 1200MG OR 1600MG A DAY) | 20235 | CAPSULE, HARD | QD | |||||||||
| 126249252 | 12624925 | 5 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 100 MG, 3X/DAY | 20235 | 100 | MG | CAPSULE, HARD | TID | ||||||
| 126249252 | 12624925 | 6 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 300 MG, 3X/DAY | 20235 | 300 | MG | CAPSULE, HARD | TID | ||||||
| 126249252 | 12624925 | 7 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 400 MG, 3X/DAY OR MAYBE MORE | 20235 | 400 | MG | CAPSULE, HARD | TID | ||||||
| 126249252 | 12624925 | 8 | SS | NEURONTIN | GABAPENTIN | 1 | UNK, 1X/DAY (TAKEN UP TO 1200MG OR 1600MG A DAY) | 20235 | CAPSULE, HARD | QD | |||||||||
| 126249252 | 12624925 | 9 | SS | LYRICA | PREGABALIN | 1 | Oral | 50MG ONE CAPSULE TWICE A DAY AS NEEDED | L61961 | 21446 | 50 | MG | CAPSULE, HARD | ||||||
| 126249252 | 12624925 | 10 | SS | LYRICA | PREGABALIN | 1 | 75 MG, UNK | 21446 | 75 | MG | CAPSULE, HARD | ||||||||
| 126249252 | 12624925 | 11 | C | NOVOLOG PEN | 2 | UNK | 0 | ||||||||||||
| 126249252 | 12624925 | 12 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1MG ONE TABLET BY MOUTH UP TO TWO TIMES A DAY AS NEEDED | 0 | 1 | MG | TABLET | |||||||
| 126249252 | 12624925 | 13 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | TABLET | |||||||||||
| 126249252 | 12624925 | 14 | C | DOLOPHINE | METHADONE HYDROCHLORIDE | 1 | Oral | 2.5 MG, 2X/DAY | 0 | 2.5 | MG | TABLET | BID | ||||||
| 126249252 | 12624925 | 15 | C | DOLOPHINE | METHADONE HYDROCHLORIDE | 1 | Oral | 5MG TWICE A DAY FOR ABOUT TWO WEEKS | 0 | 5 | MG | TABLET | BID | ||||||
| 126249252 | 12624925 | 16 | C | DOLOPHINE | METHADONE HYDROCHLORIDE | 1 | Oral | 5 MG, 3X/DAY | 0 | 5 | MG | TABLET | TID | ||||||
| 126249252 | 12624925 | 17 | C | DOLOPHINE | METHADONE HYDROCHLORIDE | 1 | Oral | 10 MG, 3X/DAY | 0 | 10 | MG | TABLET | TID | ||||||
| 126249252 | 12624925 | 18 | C | LANTUS | INSULIN GLARGINE | 1 | 0 | ||||||||||||
| 126249252 | 12624925 | 19 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126249252 | 12624925 | 1 | Diabetic neuropathy |
| 126249252 | 12624925 | 5 | Diabetic neuropathy |
| 126249252 | 12624925 | 9 | Diabetic neuropathy |
| 126249252 | 12624925 | 11 | Diabetes mellitus |
| 126249252 | 12624925 | 12 | Anxiety |
| 126249252 | 12624925 | 13 | Nausea |
| 126249252 | 12624925 | 14 | Pancreatitis chronic |
| 126249252 | 12624925 | 15 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126249252 | 12624925 | Confusional state | |
| 126249252 | 12624925 | Eye movement disorder | |
| 126249252 | 12624925 | Intentional product misuse | |
| 126249252 | 12624925 | Paraesthesia | |
| 126249252 | 12624925 | Product use issue | |
| 126249252 | 12624925 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |